Why the study?
Does a 50 mg/2 h rt-PA regimen improve safety while maintaining efficacy compared to a 100 mg/2 h rt-PA regimen in patients with acute pulmonary thromboembolism?
Population
118 patients with acute pulmonary thromboembolism and either hemodynamic instability or massive pulmonary…
Comparison
Recombinant tissue-type plasminogen activator 50… vs Recombinant tissue-type plasminogen activator…
Design
RCT, Randomly assigned, Open label
Authors
Loading...
Supports 50 mg/2 h rt-PA to reduce bleeding in acute PE; extends RCT evidence for optimized dosing in lower-weight patients.
Does a 50 mg/2 h rt-PA regimen improve safety while maintaining efficacy compared to a 100 mg/2 h rt-PA regimen in patients with acute pulmonary thromboembolism?
A lower dose of rt-PA (50 mg over 2 hours) provides similar efficacy with reduced bleeding risk compared to the standard 100 mg dose in patients with acute pulmonary embolism.
Ghanem et al. (2010) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: